• Data from multiple sources. Clinicians use data to help understand changes in patients’ health, including vital signs, physiological biometrics and environmental metrics (e.g. weather conditions, pollutant levels)
• Access to new tech. Clinicians use fast, reliable AI-diagnostic technologies (e.g. radiology and pathology), as well as new point-of-care diagnostics (e.g. liquid biopsies) to help detect and analyse molecular biomarkers.
• Clinician support. Clinical decision aids and medication management technology help clinicians co-create proactive prevention strategies with patient input.

• Skills and talent. Clinician education includes an understanding medical research and data science, as well as how to communicate diagnoses derived from genomic, digital and AI applications to patients.
• Funding. Providers have invested in data/analytics capabilities and use real-world evidence to inform disease stratification, and tailor drug dosing and regimens. Value-based care models are used to reallocate resources to where they can be most effective.
• Regulation. Organisations have adopted rigorous, nationally agreed standards of ethics and safety for the use of AI and genomics medicine.
• Data and interoperability. Providers have built an open multi-omics data ecosystem (underpinned by blockchain open source technology) and use distributed databases for secure transcription to address privacy and security concerns.

• Bioelectric technology – an implant to mitigate chronic pain. Traditionally, pain management involves multiple medications that may be ineffective. This novel device involves an imbedded spinal cord stimulating unit connected to a battery-powered magnetic transmitter (on a wearable belt) to provide effective, temporary pain control (reducing the need for some pain medication).
• Kheiron Medical Technologies is a UK-based company that has developed a mammography intelligent assessment (MIA) using AI, to detect breast cancer. The AI algorithm was tested with over three million real-world screening mammography images.

Researchers across the world are working to understand the genetic factors influencing COVID-19 susceptibility and determine the clinical efficacy of potential treatments. Researchers have openly shared their genetic sequencing of the virus and many are exploring repurposing existing drugs as an efficient and cost-effective approach to developing prevention and treatment strategies.

New possibilities are emerging as researchers bring together diagnoses and predictive analytics to evaluate how certain groups of people might respond paving the way for precision medicine and personalised treatment strategies for COVID-19.

The CovidNudge test is a fast, accurate and portable RT-PCR test that delivers results at the point-of-need in just over an hour. An average sensitivity is around 95% and specificity around 100%. The test has been authorised by the MHRA for clinical use and has subsequently obtained its CE mark.